Mario Eisenberger

Mario Eisenberger is a founding contributor to the treatment paradigm of advanced prostate cancer at Johns Hopkins and served as a key investigator in the ARASENS trial demonstrating overall survival benefit of darolutamide plus docetaxel plus ADT in mHSPC. He has contributed to establishing docetaxel and multiple hormonal agents as standards of care in prostate cancer across disease states. His decades of clinical trial leadership span hormone-sensitive to castration-resistant disease. Eisenberger's work at Hopkins has trained generations of GU oncologists who have gone on to lead major academic programs.